Inventor · disambiguated record
Martin Treder
Also filed as: TREDER MARTIN
14 granted patents·10 pending applications·104 citations·filing 2007–2024
89Inventor score
Top patents by PatentIndex Score
24 records- 0196US7705130B2Antibodies directed to HER-3 and uses thereofU3 PHARMA GMBH·Filed 2007·Granted Apr 27, 2010·84 cites·29 claims
- 0287US11535672B2Combination of an anti-CD16A antibody with a cytokineAFFIMED GMBH·Filed 2019·Granted Dec 27, 2022·8 cites·28 claims
- 0385US8771695B2Antibodies directed to HER-3 and uses thereofROTHE MIKE·Filed 2010·Granted Jul 8, 2014·8 cites·20 claims
- 0482US11510972B2Bispecific EGFR/CD16 antigen-binding proteinAFFIMED GMBH·Filed 2020·Granted Nov 29, 2022·1 cites·16 claims
- 0579US11001633B2NK cell engaging antibody fusion constructsAFFIMED GMBH·Filed 2019·Granted May 11, 2021·1 cites·14 claims
- 0679US2023059353A1Antibodies directed to her-3 and uses thereofDAIICHI SANKYO EUROPE GMBH·Filed 2022·Application pending·0 cites
- 0778US9249230B2Antibodies directed to HER-3 and uses thereofROTHE MIKE·Filed 2009·Granted Feb 2, 2016·2 cites·62 claims
- 0878US2024294647A1Uses of nk cell engaging antibody fusion constructs for treatmentsAFFIMED GMBH·Filed 2024·Application pending·0 cites
- 0973US12076384B2Bispecific EGFR/CD16 antigen-binding proteinAFFIMED GMBH·Filed 2022·Granted Sep 3, 2024·0 cites·17 claims
- 1070US11267900B2Antibodies directed to HER-3 and uses thereofDAIICHI SANKYO EUROPE GMBH·Filed 2018·Granted Mar 8, 2022·0 cites·12 claims
- 1166US2021253698A1Uses of nk cell engaging antibody fusion constructs for treatmentsAFFIMED GMBH·Filed 2021·Application pending·0 cites
- 1265US12264198B2Tandem diabody for CD16A-directed NK-cell engagementAFFIMED GMBH·Filed 2021·Granted Apr 1, 2025·0 cites·11 claims
- 1360US11180558B2Tandem diabody for CD16A-directed NK-cell engagementAFFIMED GMBH·Filed 2019·Granted Nov 23, 2021·0 cites·11 claims
- 1459US10100124B2Antibodies directed to HER-3 and uses thereofAMGEN INC·Filed 2015·Granted Oct 16, 2018·0 cites·18 claims
- 1559US2018353603A1Combination therapy including tumor associated antigen binding antibodiesCT ATLANTIC LTD·Filed 2018·Application pending·0 cites
- 1658US2025129174A1Anti-4-1-1bbxccr8 antibodies and uses thereofLTZ THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1755US2010047829A1Activated her3 as a marker for predicting therapeutic efficacyU3 PHARMA GMBH·Filed 2007·Application pending·0 cites
- 1852US2021169936A1Cryopreserved NK cells preloaded with an antibody constructAFFIMED GMBH·Filed 2021·Application pending·0 cites
- 1945US10365283B2Activated HER3 as a marker for predicting therapeutic efficacyU3 PHARMA GMBH·Filed 2016·Granted Jul 30, 2019·0 cites·9 claims
- 2044US11572415B2Multivalent FV antibodiesAFFIMED GMBH·Filed 2018·Granted Feb 7, 2023·0 cites·25 claims
- 2144US2013295091A1Combination therapy including tumor associated antigen binding antibodiesESSLINGER CHRISTOPH·Filed 2012·Application pending·0 cites
- 2241US11167029B2Combination of a CD30XCD16 antibody with a PD-1 antagonist for therapyAFFIMED GMBH·Filed 2017·Granted Nov 9, 2021·0 cites·17 claims
- 2335US2014093514A1Magea3 binding antibodiesESSLINGER CHRISTOPH·Filed 2012·Application pending·0 cites
- 2435US2014186363A1Magea3 binding antibodiesESSLINGER CHRISTOPH·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Martin Treder files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →